The U.S. Food and Drug Administration’s (FDA) vaccine advisory committee met this week to discuss requests to amend the Emergency Use Authorization (EUA) of the Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines.
Moderna asked for its EUA to include the administration of a primary series of the vaccine to infants, children and adolescents ages 6 months through 17 years.
Pfizer-BioNTech asked that its EUA include the administration of a primary series to infants and children 6 months old through age 4.
Vaccinations and/or boosters in these age groups are unnecessary.
However, based on the Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) extended history of ignoring fundamental aspects of immunology, drug safety and epidemiology — occurring as recently as last week with its approval of the Novavax COVID-19 vaccine — it was always a foregone conclusion that the committee would approve these proposals despite the significant risk to children and noteworthy lack of effectiveness.
In fact, the White House was so confident the FDA committee would authorize the vaccines, officials weeks ago announced plans to begin injections in kids as early as June 21.
Interestingly, while touting how “safe and effective” the vaccines are for children, FDA employees are all calling into the VRBPAC advisory committee meeting remotely, putatively using the COVID-19 pandemic as their reason — isn’t that more than just a little ironic?
Epidemiological evidence doesn’t support COVID shots for infants, children and adolescents
Epidemiological evidence shows infants, children and adolescents never needed COVID-19 vaccines and certainly do not need them now.
According to the Joint Committee on Vaccination and Immunisation (JCVI), 4 million doses must be administered to children 5 to 11 years old to prevent a single ICU admission.
Assuming two doses per child, that means 2 million children must risk potentially serious side effects to prevent a single child from requiring intensive care due to COVID-19…..